⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGS

SRPT

Sarepta Therapeutics, Inc.

Healthcare · Biotechnology

22.02USD

+1.0800 (+5.16%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.
Fiscal Year End12/2025
Last Quarter End06/2026 Q2
Current/T12M(USD)
1)

Issue Data

Last PxUSD / 22.02
P/E—
Dvd Ind Yld—
P/B1.52
P/S1.6
Curr EV/T12M EBITDA-141.8
Mkt Cap (USD)2.3B
Curr EV (USD)2.5B
2)

Per Share Data

EPS T12M-1.60
DPS—
Bk Val Per Sh14.47
Rev/Sh13.96
Cash/Sh7.47
Curr Shares Out105.6M
FCF/Sh0.78
3)

Cash Flow Analysis

P/CF21.0
Curr P/FCF28.4
CF/NI-0.8
Dvd P/O0.0%
Cash Gen/Cash Reqd—
Csh Dvd Cov—
CFO/Sales7.5%
Eff Interest Rate-8.2%
4)

Growth Potential

Dil EPS 1Y Gr-404.7%
Cap 1Y Gr-26.1%
BPS 1Y Gr-19.6%
R&D To Sales49.1%
Retention Rate100.0%
Rev 1Y Gr4.3%
FCF 1Y Gr10.3%
Assets 1Y Gr-15.5%
5)

Profitability

EBITDA-0.1B
EBIT-0.1B
Operating Margin-9.7%
Pretax Margin-8.9%
Net Margin-9.3%
ROA-4.0%
ROE-9.3%
ROC—
Asset Turnover0.43
6)

Structure

Current Ratio4.42
Quick Ratio2.44
Debt/Assets26.6%
Debt/Com Eq55.5%
Net Debt/EBITDA-2.81
Tot Debt/Capital35.7%
Gross Margin69.6%
EBIT/Int Exp1.8

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.